ArticleFrontiers in endocrinology2025
A novel heterozygous WFS1 variant of uncertain significance in a patient with early-onset diabetes: a case report.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the clinical presentation of a patient with early-onset diabetes and to report a novel heterozygous Methods: Clinical data were collected from the proband and his family members. Whole-exome sequencing was performed on the proband. Sanger sequencing was subsequently utilized to validate the identified variant in the proband and his parents. A review of the relevant literature was also conducted. Results: A previously unreported heterozygous missense variant in the WFS1 gene, c.1550G>C (p.Arg517Pro), was identified in the proband. Segregation analysis confirmed that this variant was inherited from his father, a non-diabetic carrier; the mother did not carry the variant. The proband's clinical phenotype was primarily characterized by early-onset diabetes and its vascular complications. No discernible neurosensory features typical of classical Wolfram syndrome-such as optic atrophy, deafness, or diabetes insipidus-were observed. Following the American College of Medical Genetics and Genomics (ACMG) guidelines, this variant was classified as one of uncertain significance (VUS). The classification was based on the following supporting criteria: PM2_Supporting (due to its extremely low allele frequency of 0.000077 in population databases) and PP3_Moderate (based on in silico predictions from the REVEL tool, which suggested a deleterious effect). Conclusion: This case report describes a novel WFS1 missense variant of uncertain significance (p.Arg517Pro) identified in a patient with early-onset diabetes. This finding contributes to the growing catalog of rare WFS1 variants and highlights the interpretive challenges they pose. It suggests that WFS1 could be considered in the genetic evaluation of selected cases of early-onset diabetes, even in the absence of full syndromic features. Prospective monitoring of asymptomatic carriers of similar variants may be warranted, pending further evidence to clarify their clinical significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.